Study Information

What’s involved?

  • 2 days & nights inpatient stay
  • 2 outpatient appointments

This clinical trial has been approved by an independent ethics committee.

About the study

This study is developing the LSALT peptide as a potential new treatment for acute kidney injury. LSALT works to prevent immune cells entering damaged parts of the body such as the kidneys. Preventing immune cells entering these parts of the body could potentially reduce the amount of damage from insults such as blockage of the blood supply.

Currently, there are no specific treatments to prevent acute kidney injury.

How do I find out more?

If you have already registered with us but would like more information about this study, please call 1800 243 733 or schedule a call back. You can also email us at reply@clinicalstudies.com.au quoting “Trio Study”.

If you are interested in participating and have not previously registered as a participant with us, fill in your details in the form below and we’ll be in touch soon!

  • 2
    Nights Inpatient Stay
  • 2
    Outpatient Visits

Minimum Eligibility Requirements:

  • Healthy Males and Females
  • Aged 18 – 55 years old
  • Body Mass Index (BMI) 18 – 32kg/m²
  • No medical conditions
  • Must not be taking any medication
Top